Cidara Therapeutics Stock Net Income
| CDTX Stock | USD 11.21 0.79 6.58% |
Cidara Therapeutics fundamentals help investors to digest information that contributes to Cidara Therapeutics' financial success or failures. It also enables traders to predict the movement of Cidara Stock. The fundamental analysis module provides a way to measure Cidara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cidara Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -22.9 M | -24.1 M | |
| Net Loss | -22.9 M | -24.1 M | |
| Net Loss | -26.8 M | -28.2 M | |
| Net Loss | (5.25) | (5.51) | |
| Net Income Per E B T | 1.02 | 0.81 |
Cidara | Net Income |
Cidara Therapeutics Company Net Income Analysis
Cidara Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Cidara Therapeutics Net Income | (22.93 M) |
Most of Cidara Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cidara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cidara Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cidara Therapeutics is extremely important. It helps to project a fair market value of Cidara Stock properly, considering its historical fundamentals such as Net Income. Since Cidara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cidara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cidara Therapeutics' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cidara Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cidara Therapeutics reported net income of (22.93 Million). This is 106.72% lower than that of the Biotechnology sector and 132.74% lower than that of the Health Care industry. The net income for all United States stocks is 104.02% higher than that of the company.
Cidara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cidara Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cidara Therapeutics could also be used in its relative valuation, which is a method of valuing Cidara Therapeutics by comparing valuation metrics of similar companies.Cidara Therapeutics is currently under evaluation in net income category among related companies.
Cidara Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cidara Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cidara Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Cidara Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Cidara Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cidara Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cidara Therapeutics' value.| Shares | U.s. Bancorp | 2023-12-31 | 262.1 K | Xtx Topco Ltd | 2023-12-31 | 161.1 K | Northern Trust Corp | 2023-12-31 | 160.6 K | Jeppson Wealth Management, Llc | 2024-03-31 | 148.7 K | Bank Of New York Mellon Corp | 2023-12-31 | 126.5 K | Callan Capital, Llc | 2023-12-31 | 103.5 K | Virtu Financial Llc | 2023-12-31 | 95.5 K | Tocqueville Asset Management L.p. | 2023-12-31 | 95 K | Raymond James Finl Svs Advisors, Inc. | 2023-12-31 | 78.9 K | Vanguard Group Inc | 2023-12-31 | 3.3 M | Nantahala Capital Management, Llc | 2023-12-31 | 3.1 M |
Cidara Fundamentals
| Return On Equity | -3.59 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.35) % | ||||
| Current Valuation | 27.08 M | ||||
| Shares Outstanding | 4.56 M | ||||
| Shares Owned By Insiders | 7.34 % | ||||
| Shares Owned By Institutions | 29.29 % | ||||
| Number Of Shares Shorted | 83.7 K | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 9.13 X | ||||
| Price To Sales | 1.30 X | ||||
| Revenue | 63.91 M | ||||
| Gross Profit | (11.23 M) | ||||
| EBITDA | (24.36 M) | ||||
| Net Income | (22.93 M) | ||||
| Cash And Equivalents | 53.08 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 4.88 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 1.93 X | ||||
| Book Value Per Share | (1.81) X | ||||
| Cash Flow From Operations | (22.43 M) | ||||
| Short Ratio | 0.71 X | ||||
| Earnings Per Share | (5.20) X | ||||
| Target Price | 81.25 | ||||
| Number Of Employees | 69 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 51.14 M | ||||
| Total Asset | 68.53 M | ||||
| Retained Earnings | (441.43 M) | ||||
| Working Capital | (6.56 M) | ||||
| Current Asset | 108.22 M | ||||
| Current Liabilities | 5.97 M | ||||
| Net Asset | 68.53 M |
About Cidara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cidara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cidara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cidara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cidara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cidara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cidara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cidara Therapeutics Stock:Check out Cidara Therapeutics Piotroski F Score and Cidara Therapeutics Altman Z Score analysis. For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Cidara Stock analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Cidara Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cidara Therapeutics. If investors know Cidara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cidara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.20) | Revenue Per Share 14.619 | Quarterly Revenue Growth 0.694 | Return On Assets (0.27) | Return On Equity (3.59) |
The market value of Cidara Therapeutics is measured differently than its book value, which is the value of Cidara that is recorded on the company's balance sheet. Investors also form their own opinion of Cidara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cidara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cidara Therapeutics' market value can be influenced by many factors that don't directly affect Cidara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cidara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cidara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cidara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.